Johnson & Johnson (JNJ) Tops Q4 EPS by 4c, Offers FY21 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Johnson & Johnson (JNJ) PT Raised to $193 at Credit Suisse
January 27, 2021 7:51 AM ESTCredit Suisse analyst Matt Miksic raised the price target on Johnson & Johnson (NYSE: JNJ) to $193.00 (from $168.00) while maintaining a Outperform rating following the company's 4Q earnings report. JNJs Med Devices results were in line with expectations of a late-Q4 slowdown in elective procedures, consistent... More
